Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2015; 21(47): 13294-13301
Published online Dec 21, 2015. doi: 10.3748/wjg.v21.i47.13294
Published online Dec 21, 2015. doi: 10.3748/wjg.v21.i47.13294
Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer
Johanna Mrena, Anne Mattila, Ilmo Kellokumpu, Department of Surgery, Central Hospital of Central Finland, 40620 Jyväskylä, Finland
Jan Böhm, Department of Pathology, Central Hospital of Central Finland, 40620 Jyväskylä, Finland
Ismo Jantunen, Department of Oncology, Central Hospital of Central Finland, 40620 Jyväskylä, Finland
Author contributions: Mrena J, Mattila A, Böhm J, Jantunen I and Kellokumpu I participated in the design of the study, acquisition of data, and article revisions; Kellokumpu I and Mrena J analyzed the data and wrote the article; all authors have approved the final version of the article.
Supported by the Central Hospital of Central Finland.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Central Hospital of Central Finland.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by verbal consent. Individuals can’t be identified according to the data presented.
Conflict-of-interest statement: This work was presented as a poster at the ISW Congress in Helsinki, Finland, August 25-29, 2013. We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Johanna Mrena, MD, PhD, Department of Surgery, Central Hospital of Central Finland, Keskussairaalantie 19, 40620 Jyväskylä, Finland. johanna.mrena@ksshp.fi
Telephone: +358-14-2695048 Fax: +358-14-2692929
Received: May 29, 2015
Peer-review started: June 3, 2015
First decision: July 19, 2015
Revised: August 17, 2015
Accepted: October 23, 2015
Article in press: October 26, 2015
Published online: December 21, 2015
Peer-review started: June 3, 2015
First decision: July 19, 2015
Revised: August 17, 2015
Accepted: October 23, 2015
Article in press: October 26, 2015
Published online: December 21, 2015
Core Tip
Core tip: Gastric cancer remains one of the most lethal malignancies worldwide. Although radical surgery with adequate lymphadenectomy is the cornerstone of curative treatment, whether D2 lymphadenectomy is applicable in Western hospitals is not clear, despite the low reported morbidity and mortality rates and survival benefit. This single-center study of 109 patients demonstrates that D2 lymphadenectomy can be performed with relatively low mortality (1.8%) and morbidity (26.6%). Five-year survival rates were 45.0% (overall) and 53.0% (disease-specific). Therefore, D2 gastrectomy can be considered as a safe surgical option for gastric cancer.